{
  "ptid_time": "041_S_5097_2015-04-01",
  "img_path": "/data/qiuhui/data/adni/images/041_S_5097/2015-04-01/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 44,126 mm³, 47.0% above the reference mean. With a Z-score of 1.12 (86.8th percentile), this represents mild enlargement; hippocampal volume measures 6,134 mm³, 23.6% below the reference mean. With a Z-score of -2.36 (0.9th percentile), this represents significant atrophy; whole brain volume measures 975,484 mm³, 14.0% below the reference mean. With a Z-score of -1.98 (2.4th percentile), this represents moderate atrophy; entorhinal cortex volume measures 3,168 mm³, 25.7% below the reference mean. With a Z-score of -1.78 (3.8th percentile), this represents moderate atrophy; fusiform gyrus volume measures 13,213 mm³, 33.6% below the reference mean. With a Z-score of -2.80 (0.3th percentile), this represents significant atrophy; middle temporal gyrus volume measures 16,967 mm³, 24.3% below the reference mean. With a Z-score of -2.00 (2.3th percentile), this represents significant atrophy. ",
  "text_data": "Age is 69.5 years. Gender is Male. Education: 16 years. MMSE: 28.0. MoCA: 24.0. Logical Memory: 16.0. APOEε4 alleles: 0.0. Biomarker levels: Florbetapir (AV45): 1.11 SUVR (normal ); Amyloid beta: 1098.00 pg/mL (normal ); Total tau: 199.10 pg/mL (normal ); Phosphorylated tau: 16.20 pg/mL (normal ). ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The imaging data shows significant atrophy in key Alzheimer's-related regions (hippocampus, fusiform gyrus, middle temporal gyrus) alongside moderate whole-brain and entorhinal cortex atrophy, suggesting neurodegeneration. However, cognitive scores (MMSE 28, MoCA 24) are borderline for MCI, and biomarkers (Aβ, tau, AV45) are normal, which is atypical for typical Alzheimer’s pathology.  \n\n**Diagnosis:** **MCI** (mild cognitive impairment)  \n**Confidence:** **Medium** (due to conflicting imaging and biomarker findings; neurodegeneration is evident, but the absence of biomarker support lowers certainty for Alzheimer’s-type dementia).",
  "timestamp": "2025-07-26T07:25:25.647465"
}